General
Epigenetic Profiles Distinguish Pleural Mesothelioma from Normal Pleura and Predict Lung Asbestos Burden and Clinical Outcome
Cancer Research. 2009 Jan 1;69(1):227-34. [Link] Christensen BC, Houseman EA, Godleski JJ, Marsit CJ, Longacker JL, Roelofs CR, Karagas MR, Wrensch MR, Yeh RF, Nelson HH, Wiemels JL, Zheng S, Wiencke JK, Bueno R, Sugarbaker DJ, Kelsey KT. Department of Community Health, Center for Environmental Health and Technology, Brown University, 70 Ship Street, Providence, RI…
Read MoreMalignant mesothelioma
Orphanet Journal of Rare Diseases. 2008 Dec 19;3:34. [Link] Moore AJ, Parker RJ, Wiggins J. Department of Respiratory Medicine, Wexham Park Hospital, Wexham, Slough, Berkshire, UK. a.moore@ic.ac.uk Abstract Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica…
Read MoreA review of mesothelioma information on the World Wide Web
Journal of Thoracic Oncology. 2009 Jan;4(1):102-4. [Link] Tan BH, Kostapanagiotou K, Jilaihawi AN. Department of Thoracic Surgery, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom. benjamin.tan@ed.ac.uk Abstract Introduction: The Internet is a widely used information resource for patients with mesothelioma. The goal of this study is to assess the content and quality of mesothelioma information presented…
Read MoreAsbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population
Industrial Health. 2008 Dec;46(6):535-40. [Link] Park EK, Hannaford-Turner KM, Hyland RA, Johnson AR, Yates DH. Research and Education Unit, Workers’ Compensation Dust Diseases Board of NSW, Sydney, Australia. Abstract Asbestos is a fibrous silicate which is recognized as causing a variety of lung disorders including malignant mesothelioma of the pleura, lung cancer and asbestosis. Asbestos…
Read MoreThe CREST biorepository: a tool for molecular epidemiology and translational studies on malignant mesothelioma, lung cancer, and other respiratory tract diseases
Cancer Epidemiology Biomarkers & Prevention. 2008 Nov;17(11):3013-9. [Link] Ugolini D, Neri M, Canessa PA, Casilli C, Catrambone G, Ivaldi GP, Lando C, Marroni P, Paganuzzi M, Parodi B, Visconti P, Puntoni R, Bonassi S. Department of Oncology, Biology and Genetics, University of Genoa, National Cancer Research Institute, Largo R. Benzi, 10-16132 Genoa, Italy. donatella.ugolini@istge.it Abstract…
Read MoreUS mesothelioma patterns 1973-2002: indicators of change and insights into background rates
European Journal of Cancer Prevention. 2008 Nov;17(6):525-34. [Link] Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. Exponent Inc., Health Sciences Practice, New York, New York, USA. jteta@exponent.com Abstract Mesothelioma rates are declining toward background levels, although estimates of the background rate have varied. We expanded upon earlier analyses and provided a data-based estimate…
Read MoreAsbestos disease in Australia: looking forward and looking back
New Solutions: A Journal of Environmental and Occupational Health Policy . 2008;18(3):361-73. [Link] LaMontagne AD, Hunter CE, Vallance D, Holloway AJ. McCaughey Centre: VicHealth Centre for the Promotion of Mental Health and Community Wellbeing, School of Population Health, University of Melbourne, 207 Bouverie Street, Melbourne, Victoria 3010, Australia. alamonta@unimelb.edu.au Abstract This article provides an overview…
Read More‘Hands of Time’: the experience of establishing a support group for people affected by mesothelioma
European Journal of Cancer Care. 2008 Nov;17(6):585-92. Epub 2008 Sep 12. [Link] Moore S, Teehan C, Cornwall A, Ball K, Thomas J. Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey, UK. sally.moore@rmh.nhs.uk Abstract Expertise and management of mesothelioma are known to vary throughout the UK. The support needs of people with mesothelioma and their…
Read MoreSystemic Treatments for Mesothelioma: Standard and Novel
Current Treatment Options in Oncology. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3. [Link] Kindler HL. Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu Abstract Systemic therapy is the only treatment option for the majority of mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and locally advanced disease often preclude surgery. For…
Read MoreThe Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus
Journal of Surgical Oncology. 2008 Sep 15;98(4):258-62. [Link] Baratti D, Kusamura S, Deraco M. Department of Surgery, National Cancer Institute, Milan, Italy. Abstract Peritoneal surface malignancies (PSM) have been traditionally regarded as uniformly terminal conditions. The combination of cyto-reductive surgery and perioperative intraperitoneal chemotherapy has changed PSM management from palliation to possible cure. Due to…
Read More